| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2021: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Androgen deprivation therapy (ADT) is effective in the treatment of hormone-sensitive prostate cancer (HSPC), but the prognosis for patients who develop resistance to ADT and progress to castration-resistant prostate cancer (CRPC) is poor. However, there are no predictive markers that can predict the acquisition of castration resistance and provide useful information for treatment decisions. In this study, we constructed a diagnostic model to differentiate HSPC and CRPC using an immunoglobulin N-glycan signature and a machine learning model. The constructed diagnostic model diagnoses CRPC with an AUC of 0.88 or higher and is expected to be useful in predicting CRPC in the future.
|
